Deutsche Bank downgraded Veradigm to Hold from Buy with a price target of $10, down from $15. The company recently announced initial financial guidance for fiscal 2024, calling the year a reset and then for accelerating growth and margin expansion in the years ahead, the analyst tells investors in a research note. The firm says Veradigm believes 2024 growth will largely be driven by payer and life sciences, as the company looks to become more of a data and analytics company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDRX:
- Veradigm Highlights Strategies at Barclays Healthcare Conference
- Sprinklr to replace Veradigm in S&P 600 at open on 3/4
- Veradigm: Strategic Acquisition, Stock Plans Amidst Nasdaq Challenges
- Veradigm provides update on financial restatement process
- Veradigm to acquire ScienceIO for $140M in cash
Questions or Comments about the article? Write to editor@tipranks.com